Jasper Chen, MD
Psychiatry · Cheyenne, WYNPI 1922121318
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,547 of the $103,589 with a category attached, or 90.3%. Otsuka America Pharmaceutical, Inc. accounts for 99.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $42,545, 3.6 times the $11,794 reported in 2019. Among psychiatry clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $863.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$103K
- Amgen$316
- Abbott$150
- Teva Pharmaceuticals USA, Inc.$104
- Otsuka Pharmaceutical Development & Commercialization, Inc.$80
What the payments were for
- Speaking & faculty fees$93,54790%
- Travel & lodging$7,4427%
- Food & beverage$2,6003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 109 | $102,939 |
| Amgen | 3 | $316 |
| Abbott | 1 | $150 |
| Teva Pharmaceuticals USA, Inc. | 3 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$101,767
- ABILIFY ASIMTUFII$64,830
- INFINITY$150
- AIMOVIG$125
How this compares
$103,589 in reported general payments places this provider in the 95th percentile of 29 psychiatry providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 11 | $820 |
| Duloxetine Hcl | 19 | $495 |
| Gabapentin | 24 | $485 |
| Buspirone Hcl | 19 | $293 |
| Mirtazapine | 13 | $253 |
| Hydroxyzine Pamoate | 32 | $222 |
| Trazodone Hcl | 39 | $199 |
| Quetiapine Fumarate | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cheyenne
- Sukhpreit SohiCheyenne$586
- David FohrmanCheyenne$200
- Justin RomanoCheyenne$180
- Benjamin JohnsonCheyenne$160
- Kathryn HopfenspergerCheyenne$55
- Arla MisticaCheyenne$22
- James BrowningCheyenne$18
- Amy ButterworthCheyenne$0
- Christopher ReyburnLaramie$2K
- Mark VuoloCasper$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.